Simple Clinical, Laboratory Parameters Predict Mortality in Pancreatic Adenocarcinoma
the Cancer Therapy Advisor take:
The Khorana score and other associated factors of early mortality help identify high-risk patients after surgical resection for pancreatic cancer, according to an article published online in Cancer.
The cohort study examined 334 patients with a median age of 67 years who underwent surgical resection for pancreatic cancer between January 2006 and June 2013. Of the enrolled patients, 50% were female and 86% were white.
The primary tumor site was the pancreatic head for 73% of patients. Of the tumors, 67% were T3 and 63% were N1.
High-risk patients were defined as having a Khorana score greater than three. Out of the 334 patients, 152 (47%) were considered to be high risk. The median Khorana score was determined to be two.
The two major adjunctive treatments for patients included chemotherapy and radiotherapy (70% and 40%, respectively).
There was an observed difference of the postoperative 30 day mortality rate and the 6-month mortality rate between patients who were not determined to be high risk and those who were.
For those patients who weren’t high-risk, the 30-day mortality rate was 0.9% and the 6-month mortality rate was 9.4%.
High-risk patients experienced significantly higher mortality rates, with 13.4% having 30-day and 5.6% experiencing 6-month mortality (P=0.02).
The study suggests that future research focus on preoperative interventions for patients who are considered high-risk for early mortality.
The Khorana score and other factors of early mortality help identify high-risk patients after surgical resection for pancreatic cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma